Midostaurin (6) and therecently approved quizartinib are the only FDA-approved FLT3 inhibitors as afirst-line treatment in combination with chemotherapy for adult patients withnewly-diagnosed FLT3-ITD-positive AML. Here, FLT3 is linked to acute myeloid leukemia.